Amicus Shares Fall on Drug Failure in Fabry Disease Study

Amicus Therapeutics Inc. shares fell the most ever after the company said its experimental treatment for Fabry disease failed in a clinical trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.